TG Therapeutics Inc (NASDAQ: TGTX) kicked off on Monday, down -1.85% from the previous trading day, before settling in for the closing price of $23.83. Over the past 52 weeks, TGTX has traded in a range of $6.46-$26.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 2506.46%. While this was happening, its average annual earnings per share was recorded -41.67%. With a float of $137.98 million, this company’s outstanding shares have now reached $151.42 million.
Let’s determine the extent of company efficiency that accounts for 264 employees.
TG Therapeutics Inc (TGTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of TG Therapeutics Inc is 10.88%, while institutional ownership is 59.32%. The most recent insider transaction that took place on Jun 20 ’24, was worth 275,791. In this transaction Director of this company sold 16,348 shares at a rate of $16.87, taking the stock ownership to the 105,195 shares. Before that another transaction happened on Jun 17 ’24, when Company’s Director sold 9,585 for $16.39, making the entire transaction worth $157,098. This insider now owns 99,293 shares in total.
TG Therapeutics Inc (TGTX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported 0.73 earnings per share (EPS), higher than consensus estimate (set at 0.12) by 0.61. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -41.67% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Take a look at TG Therapeutics Inc’s (TGTX) current performance indicators. Last quarter, stock had a quick ratio of 2.83. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.44. Likewise, its price to free cash flow for the trailing twelve months is 53.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.60, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach 0.74 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
Looking closely at TG Therapeutics Inc (NASDAQ: TGTX), its last 5-days average volume was 2.12 million, which is a drop from its year-to-date volume of 3.76 million. As of the previous 9 days, the stock’s Stochastic %D was 22.43%. Additionally, its Average True Range was 1.20.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 73.16%, which indicates a significant increase from 19.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.39% in the past 14 days, which was lower than the 57.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.26, while its 200-day Moving Average is $17.93. However, in the short run, TG Therapeutics Inc’s stock first resistance to watch stands at $24.09. Second resistance stands at $24.78. The third major resistance level sits at $25.17. If the price goes on to break the first support level at $23.01, it is likely to go to the next support level at $22.62. Now, if the price goes above the second support level, the third support stands at $21.93.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
The company with the Market Capitalisation of 3.62 billion has total of 154,543K Shares Outstanding. Its annual sales at the moment are 233,660 K in contrast with the sum of 12,670 K annual income. Company’s last quarter sales were recorded 73,470 K and last quarter income was 6,880 K.
